

Target Healthcare REIT

Funded for growth opportunities

Target has recently raised an additional £94m in new equity and has extended its debt facilities by £40m, providing the capital resources to pursue an immediate investment pipeline of more than £100m. The strength of the pipeline and flexible debt facilities limit the drag from cash, while the expanded portfolio offers further diversification and scale economies to counter increasing asset prices. The shares have slightly derated during the process and offer an attractive 5.8% yield and growing dividend, which we expect to be fully covered on a fully invested basis.

Year end	Revenue (£m)	EPRA net earnings* (£m)	EPRA EPS* (p)	EPRA NAV/ share (p)	DPS (p)	Price/EPRA NAV/share (x)	Yield (%)
06/16	16.9	8.1	4.7	100.6	6.18	1.10	5.6
06/17	23.6	12.2	4.8	101.9	6.28	1.08	5.7
06/18e	29.1	15.9	5.6	104.2	6.45	1.07	5.8
06/19e	36.3	20.8	6.1	105.8	6.58	1.05	6.0

Note:*EPRA earnings exclude revaluation movements, non-cash income arising from the accounting treatment of lease incentives and guaranteed rent review uplifts, and the costs of acquisitions.

Significant new capital for growth

With £94m of additional equity and borrowing facilities increased to £130m, our revised estimates allow for £140m of new committed investment by the end of FY19, with the majority (c £120m) in the current year. Including existing commitments, we believe this would represent full investment, with borrowing facilities fully drawn and a net LTV of c 25%. The equity raising (at 108p) has no material effect on EPRA NAV per share (104.4p at end-2017) despite acquisition costs. Full dividend cover is delayed, but at an assumed 6.25% average yield on investment we expect 102% cover in FY20, as investments made by the end of FY19 make a full contribution to earnings.

Strong pipeline for swift deployment

In addition to £20m of existing commitments, advanced negotiations are underway for the immediate acquisition of two forward funding assets for an aggregate £19m (including costs) as well as for a £61m (including costs) pipeline of additional assets, including a modern care home and 4 forward funding assets. Negotiations have also begun regarding the potential acquisition of a portfolio of care homes for an estimated £62m (including costs). Clearly, the investment manager continues to identify a range of opportunities that meet its investment criteria and while the acquisitions completed may differ from those identified, the prospects for swift investment of the additional capital appear strong.

The yield has increased with NAV premium reduced

Since last October, when Target flagged the scale of its investment opportunity, in excess of capital resources, the premium to EPRA NAV has drifted lower, with the yield increasing. In part this may reflect more hawkish market interest rate expectations, but leaves the shares with an attractive and growing 5.8% yield and more modest 7% premium to NAV.

Update on portfolio growth

Real estate

16 March 2018

Price	110.5p
Market cap	£375m

Net debt (£m) as at 31 December 2017	66.1
Gross LTV as at 31 December 2017	24.2%
Shares in issue	339.2m
Free float	90%
Code	THRL
Primary exchange	LSE
Secondary exchange	N/A

Share price performance



%	1m	3m	12m
Abs	0.9	4.7	0.0
Rel (local)	1.7	9.0	1.5
52-week high/low		122.5p	105.6p

Business description

Target Healthcare REIT invests in modern, purpose-built residential care homes in the UK let on long leases to high-quality care providers. It selects assets according to local demographics and intends to pay increasing dividends underpinned by structural growth in demand for care.

Next events

Interim results	March 2018

Analysts

Martyn King +44 (0)20 3077 5745 Andrew Mitchell +44 (0)20 3681 2500

financials@edisongroup.com

Edison profile page

Target Healthcare REIT is a research client of Edison Investment Research Limited



Continuing accretive growth opportunities

Target has for some time made clear that its intention is to grow its portfolio further, with a view to capturing the positive spread between rental income and funding costs as well as operational efficiencies, but also to continue to diversify the portfolio both by the number of assets and tenants. When the company announced its FY17 results in October 2017, it stated that the investment manager was performing due diligence on a range of further acquisition opportunities that it believed would meet its investment criteria and in aggregate had a value in excess of the capital that was available.

It invested c £34m (including costs) during the quarter ended 31 December, including three significant care home acquisitions, but that was only a part of the opportunity that had been identified. That took end-2017 debt to £81m (from its £90m of debt facilities at the time), and effectively represented full or near full deployment, in a total of 18 care home acquisitions, of the £84m proceeds from the equity raise that took place April 2016.

New debt and equity capital raised

The first stage of increasing the capital resources available to Target was to negotiate a new £40m revolving credit facility, with an initial three-year term and an option for two one-year extensions. However, gross gearing, or borrowing as a percentage of gross assets (overwhelmingly represented by the investment portfolio), is limited to 35% at the time of drawdown. In practice, a lower level of c 20% is targeted by the board over the medium term, while exceeding this occasionally to fund the growth of the portfolio also limited cash drag. The second stage of the capital raising process was therefore to increase equity capital resources. At the beginning of February Target announced an initial placing, open offer and offer for subscription at 108p (a premium to the end-December 2017 EPRA NAV per share of 104.4p), subsequently raising gross proceeds of £94m through the issue of 87.0m new shares in the initial issues. Shareholders also gave approval for a one-year placing programme, allowing for further issuance, up to a maximum 150m shares including the initial issues, at the discretion of the company, as and when it identifies suitable acquisition opportunities.

With the prospectus to accompany the share issue, Target stated that it had identified a pipeline of investment opportunities comprising:

- £39m of imminent acquisitions and capital commitments in respect of the existing portfolio. The imminent acquisitions comprised two forward funding assets for which negotiations were at an advanced stage, with an aggregate consideration of up to £19m (including the costs of acquisition). The assets are in Shropshire and Lancashire and Target has entered into non-binding heads of terms, expecting to commit to funding and acquiring both assets by the end of March 2018.
- A £61m (including costs) pipeline of additional assets, also at an advanced stage of negotiation, comprising a modern care home in Birmingham and four additional forward funding opportunities in Powys, Buckinghamshire and two in Oxfordshire.

Target's intention is to optimise the deployment of the £94m net proceeds from the initial issue, and its debt facilities in the acquisition of the imminent and pipeline assets. Depending on the timing of investments, some of the revolving debt may be repaid for a time and should the acquisition of these assets not complete, Target intends to direct its available resources towards the acquisition of further properties that have been identified by the investment manager. This includes a portfolio of care homes with an estimated acquisition value of £62m (including costs).



The investment market is competitive, requiring selectivity

While longer-term funding for adult social care continues to be debated publicly, and the problems facing the wider industry inevitably receive much media attention, what is often overlooked is the ability of well-managed operators, with efficiently run homes, in locations with a good demand-supply balance to effectively and sustainably meet this need.

Investor interest in such homes remains strong and is continuing to drive a tightening in valuation yields, especially for purpose-built homes, in prime locations, focused on self-funded residents. The average net initial yield on Target's portfolio tightened further in the quarter to end-2017, to 6.58% versus 6.69% in September. While this is positive for NAV, the yield tightening also highlights the strong competition for quality assets in the market.

In this environment, selective investment, in homes that are most likely to effectively and profitably meet care needs over many years is essential and we believe that Target remains focused on building just such a portfolio. Target has always put a strong emphasis on the careful selection of operators and growing share of forward funded assets in the investment pipeline gives access to modern, purpose-built homes. Target is not a developer and forward funding agreements allow it to acquire pre-let care homes at completion, meanwhile funding the development cost. So long as the location and operator of the home is carefully selected, the additional risk compared with the acquisition of operational homes should be minimal.

Earnings updated to include capital raise and investment

We have updated our forecasts to include the equity issue, the increase in total debt facilities and a revised assessment of how the increased funds are likely to be deployed. In short, given the scale of potential opportunities to which management refers, we assume the increased resources to be fully invested by the end of FY19. However, the FY19 investment will not fully contribute to earnings in that year, so we have extended our forecast period out to FY20 to illustrate the likely benefit. The FY20 forecast assumes no new investment and is perhaps best seen as an illustration of the potential earnings, dividend paying capacity and dividend cover that the new level of capital resources (equity and debt), fully invested, is capable of generating.

Our revised forecasts assume:

- An increase in the number of shares by 87.0m to 339.2m, with gross proceeds of £94.0m less issue costs that we have assumed to be £1.4m or 1.5%.
- An aggregate commitment to new investment of c £140m (including costs) between December 2017 (H118) and June 2019 (H219). This splits c 50:50 between investment in let standing assets and commitments to forward funding agreements.
- An aggregate cash investment of c £151m between H118 and end-FY20. The investment is spread over a longer timeframe than the commitments because of the forward funding element and the aggregate amount exceeds the total committed because of commitments, made prior to H118, brought forward.
- The aggregate amount of new investment commitment is broadly equivalent to the aggregate value of the Imminent Acquisition Assets, the Pipeline Assets, and the potential portfolio acquisition, although the actual assets acquired, and the amounts committed to, may differ.
- We have assumed a 6.25% yield on all new investment, earned from the point of cash investment. Each asset will differ, but the assumed average, lower than the net initial yield of 6.58% reflected in the December 2017 portfolio valuation recognises the continuing strong investor interest in the asset class and market yield tightening. Income from the forward funding



- assets takes the form of coupon payment on the funding provided, and reported as other income, until rental income is reported at completion.
- In our view the investments that we have assumed represent full investment of the capital resources now available, with the £130m of debt facilities fully drawn and a net LTV of 25.7%.

Faster than previously assumed investment increases our revenue forecasts for FY18 and FY19. The negative impact on EPRA EPS in FY18 from the increased number of shares is minimal, aided by Target having a strong pipeline of opportunities to quickly deploy the funds raised, as well as the ability to reduce the revolving debt usage in the near term to manage cash drag. The impact on FY19 is positive as a result of higher revenues and the effect of operational gearing. EPRA NAV is little changed, with the benefit to NAV per share from share issuance at a c 3.4% premium to the December 2017 EPRA NAV per share of 104.4, effectively off-setting share issuance costs and the additional property acquisition costs that we have assumed as a result of increased investment.

Exhibit 1: Forecast revisions												
Revenue (£m)				E	PRA EPS	(p)	EPRA NAV/share (p)			DPS (p)		
	Old	New	Change (%)	Old	New	Change (%)	Old	New	Change (%)	Old	New	Change (%)
June-18e	28.9	29.1	0.8	5.69	5.58	-1.9	104.1	104.2	0.1	6.45	6.45	0.0
June-19e	34.2	36.3	5.9	5.87	6.12	4.3	106.5	105.8	(0.7)	6.58	6.58	0.0
June-20e	N/A	38.6	N/A	N/A	6.86	N/A	N/A	108.4	N/A	N/A	6.71	N/A
Source: Ed	Source: Edison Investment Research											

Our forecasts indicate that EPRA earnings per share will be 87% of DPS in the current year, a slower increase on the 77% reported in FY17. This increases to 93% in FY19, with full cover og 103% achieved in FY20. The FY20 cover may be regarded as indicating the potential for full dividend cover on a fully invested basis. In reality, this may be deferred if Target continues to identify suitable further investment opportunities and raises additional capital (equity and debt) to fund these.

Strong yield attraction

Within the broad commercial property universe, Target is differentiated by its focus on care home assets, which appear primed to benefit from the ongoing demographic shifts, and the very long nature of leases arrangements in the sub-sector. Target's weighted average unexpired lease term (WAULT) of 28.9 years at 31 December 2017 is one of the longest of all REITs, and combined with upwards-only rent reviews, mostly capped-and-collared RPI-linked, there is considerable visibility to future contracted rental income in real terms.

In Exhibit 2 we show a summary of the valuations and share price performances for a small group of companies that similarly target long leases. The closest comparators are perhaps Assura, MedicX and Primary Health Properties, all investors in modern primary healthcare facilities, primarily used by GPs. The average WAULT is a little lower at c 15 years, but the tenant covenant is strengthened by having NHS backing, directly or indirectly. In broad terms, the group shown in Exhibit 2 has outperformed the FTSE All Share Index over the past 12 months, and also offer a higher yield, supporting valuations above NAV.



Exhibit 2: Valuation comparison with other long lease property investors.												
	Price	Market cap	P/NAV*	Yield**		Share price	performance					
	(p)	(£m)	(x)	(%)	1 month	3 months	12 months	From 12M high				
Assura	58	1,387	1.10	4.5%	0%	-1%	3%	-10%				
Medicx	83	356	1.06	7.3%	-1%	1%	-6%	-11%				
Primary Health Properties	117	729	1.17	4.6%	2%	3%	6%	-5%				
Secure Income REIT	371	855	1.00	3.8%	4%	3%	7%	-3%				
Tritax	148			4.5%	4%	2%	3%	-3%				
Average		647	1.08	5.2%	2%	2%	3%	-6%				
Target Healthcare	112	378	1.07	5.8%	3%	-2%	-2%	-10%				
FTSE All-Share Index					1%	-3%	0%	-7%				

Source: Bloomberg data as at 12 March 2018. Edison forecasts for MedicX, Primary Health Properties, Target. *Last published NAV. **Yield based on expected current year dividend.

Target's share price is c 10% off its 12-month high (of 123p in August 2017) and its P/NAV is down from a peak of c 1.20x. We suspect that increased expectations for interest increases and the recent equity issue are the main contributing factors. Its prospective yield is well above the average for the group, and second only to MedicX, and its P/NAV is very slightly below the average. As noted above, our forecasts include further dividend growth and the potential for full dividend cover in the year to June 2020.



Voor to 20 June (£000s)	2014	2045	2046	2047	2040	2040	2020
Year to 30 June (£000s) INCOME STATEMENT	2014	2015	2016	2017	2018e	2019e	2020
Rent revenue	3,817	9,898	12,677	17,760	22,838	28,242	31,602
Movement in lease incentive or rent review	1,547	3,760	4,136	5,127	5,414	5,414	5,414
Rental income	5,364	13,658	16,813	22,887	28,252	33,656	37,016
Other income	0	66	61	671	861	2,604	1,576
Total revenue	5,364	13,724	16,874	23,558	29,113	36,259	38,592
Gains/(losses) on revaluation	(2,233)	(839)	425	2,211	151	1,373	3,34
Cost of corporate acquisitions	0	(174)	(998)	(626)	0	0	(14.00)
Total income	3,131	12,711	16,301	25,143	29,265	37,632	41,933
Management fee Other expenses	(648) (780)	(1,524) (880)	(2,654) (992)	(3,758) (1,236)	(4,158) (1,700)	(4,801) (2,100)	(4,881
Total expenditure	(1,428)	(2,404)	(3,646)	(4,994)	(5,858)	(6,901)	(7,081
Profit before finance and tax	1,703	10,307	12,655	20,149	23,407	30,731	34,85
Net finance cost	190	(716)	(929)	(808)	(1,945)	(3,183)	(3,389
Profit before taxation	1,893	9,591	11,726	19,341	21,462	27,548	31,46
Тах	(4)	(39)	(24)	(219)	0	0	,
Profit for the year	1,889	9,552	11,702	19,122	21,462	27,548	31,46
Average number of shares in issue (m)	105.2	119.2	171.7	252.2	284.8	339.2	339.
FRS earnings	1,889	9,552	11,702	19,122	21,462	27,548	31,46
Adjusted for rent arising from recognising	(1,547)	(3,760)	(4,136)	(5,127)	(5,414)	(5,414)	(5,414
guaranteed rent review uplifts + lease incentives	0.000	200	(405)	(0.044)	(454)	(4.070)	(0.700
Adjusted for valuation changes	2,233	839	(425)	(2,211)	(151)	(1,373)	(2,782
Adjusted for corporate acquisitions	0	174	998	420	15.007	0 761	22.00
EPRA earnings Adjustment for performance fee	2,575 150	6,805 466	8,139 871	12,204 997	15,897 960	20,761 960	23,26 96
Group adjusted EPRA earnings	2,725	7,271	9,010	13,201	16,857	21,721	24,22
FRS EPS (p)	1.80	8.02	6.81	7.58	7.54	8.12	9.2
EPRA EPS (p)	2.45	5.71	4.74	4.84	5.58	6.12	6.8
Adjusted EPS (p)	2.59	6.10	5.25	5.23	5.92	6.40	7.1
Dividend per share (declared)	6.00	6.12	6.18	6.28	6.45	6.58	6.7
BALANCE SHEET							***
Investment properties	81,422	138,164	200,720	266,219	399,057	448,587	465,14
Trade and other receivables	0	2,530	3,742	3,988	5,061	5,816	6,06
Non-current assets	81,422	140,694	204,462	270,207	404,118	454,403	471,21
Trade and other receivables	6,524	6,457	13,222	25,629	24,261	29,675	35,08
Cash and equivalents	17,125	29,159	65,107	10,410	10,723	9,942	1,25
Current assets	23,649	35,616	78,329	36,039	34,984	39,617	36,34
Bank loan	(11,764)	(30,865)	(20,449)	(39,331)	(75,699)	(125,279)	(130,000
Other non-current liabilities	(44.704)	(2,530)	(4,058)	(3,997)	(3,997)	(3,997)	(3,997
Non-current liabilities Trade and other payables	(11,764) (3,089)	(33,395)	(24,507) (5,002)	(43,328)	(79,696) (5,981)	(129,276) (5,981)	(133,997 (5,981
Current Liabilities	(3,089)	(3,623)	(5,002)	(5,981) (5,981)	(5,981)	(5,981)	(5,981
Net assets	90,218	139,292	253,282	256,937	353,425	358,764	367,57
Period end shares (m)	95.2	142.3	252.2	252.2	339.2	339.2	339.
IFRS NAV per ordinary share	94.7	97.9	100.4	101.9	104.2	105.8	108.4
EPRA NAV per share	94.7	97.9	100.6	101.9	104.2	105.8	108.4
CASH FLOW					-		
Profit before tax	1,893	9,591	11,726	19,341	21,462	27,548	31,46
Adjusted for							
Net interest payable	(190)	716	929	808	1,945	3,183	3,38
Revaluation gains on property portfolio	686	(2,921)	(4,787)	(7,339)	(5,567)	(6,789)	(8,757
Cost of corporate acquisitions	0	0	0	626	0	0	
Change in receivables/payables	783	695	1,038	(9,042)	5,709	(756)	(248
Net interest paid	161	(514)	(681)	(615)	(1,577)	(2,603)	(3,318
Tax paid	0	(47)	(164)	(543)	0 01 070	0	22.52
Net cash flow from operating activities Purchase of investment properties	3,333 (51,894)	7,520 (51,736)	8,061 (34,833)	3,236 (37,698)	21,972 (132,687)	20,584 (48,157)	22,53 (13,219
Acquisition of subsidiaries	(51,094)	(5,845)	(27,091)	(25,552)	(132,007)	(40, 137)	(13,218
Net cash flow from investing activities	(51,894)	(57,581)	(61,924)	(63,250)	(132,687)	(48,157)	(13,219
Issue of ordinary share capital (net of expenses)	44,520	46,644	97,501	(03,230)	92,590	(40,137)	(13,213
Sale of shares from treasury	0	0	14,799	0	0	0	
(Repayment)/drawdown of loans	8,646	22,525	(12,808)	20,906	36,000	49,000	4,65
Dividends paid	(4,364)	(7,074)	(9,681)	(15,589)	(17,562)	(22,208)	(22,652
Net cash flow from financing activities	48,802	62,095	89,811	5,317	111,028	26,792	(18,002
Net change in cash and equivalents	241	12,034	35,948	(54,697)	313	(781)	(8,691
Opening cash and equivalents	16,884	17,125	29,159	65,107	10,410	10,723	9,94
Closing cash and equivalents	17,125	29,159	65,107	10,410	10,723	9,942	1,25
Debt	(11,764)	(30,865)	(20,449)	(39,331)	(75,699)	(125,279)	(130,000
Net cash/(debt)	5,361	(1,706)	44,658	(28,921)	(64,976)	(115,337)	(128,749
Net LTV	0.0%	0.0%	0.0%	10.5%	15.5%	24.1%	25.7%



Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector Easion in Nesting and advisory of company, with offices in North America, Europe, the wholide scalar land scalar in Assarbat. The heart of businers and work-relevance equity research platform to provide services including investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholes ale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Pty Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.ediso

Copyright 2018 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Target Healthcare REIT and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Investment Research Pty Ltd (Corporate Authorised Representative (1252501) of Myonlineadvisers Pty Ltd (AFSL: 427484)) and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this rest and consequently active several test and several test and the information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2018. "FTSE@" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.